Hot Low Price Companies To Invest In Right Now

This article was written by�Oilprice.com, the leading provider of energy news in the world. Also check out these related articles:

OPEC & Russia's Vulnerability and America's Ingenuity
Saudi Arabia: Producing More Crude, Selling Less?

OPEC Secretary-General Abdalla Salem el-Badri says he doesn't expect demand for the cartel's oil or its production levels to change in the coming year, and he is urging member states not to be alarmed by oil's current low prices.

"Don't panic," el-Badri�said Oct. 29�at an impromptu news conference in London, where he was attending a conference. "I am sure the market will balance itself."

The concern, if not the panic, already is present. The price of the global petroleum benchmark, Brent crude, plunged a little more than $87 a barrel the day he made those comments -- nearly $30 less than it was in June, a loss of about one-fourth of its value.

Al-Badri shrugged off this loss, saying he wasn't worried because price fluctuations don't reflect "the fundamentals" of the oil market. "Demand is still growing, supply is also growing. OPEC is reviewing the situation,"�he said. "There is nothing wrong with the market."

10 Best India Stocks To Own For 2015: Elray Resources Inc (ELRA)

Elray Resources, Inc., incorporated on December 13, 2006, is an exploration stage company. The Company was engaged in the acquisition and exploration of mineral properties with a view to exploiting any mineral deposits discovered.

Elray owned a 100% interest in Porphyry Creek, a 90 square kilometer gold and copper claim located in Cambodia. During the year ended December 31, 2011, the Company has not generated any revenues.

Advisors' Opinion:

• [By CRWE]

  Today, ELRA remains (0.00%) +0.000 at $.160 thus far (ref. google finance Delayed:� 1:13PM EDT July 2, 2013).

  Elray Resources, Inc. through its online gaming and turnkey solution subsidiary Elray Gaming, previously reported the launch and operations of the Golden Galaxy online casino.

  Golden Galaxy is a licensed online casino, and whilst it complies fully with the UIGEA (The Unlawful Internet Gambling Enforcement Act of 2006) and does not accept US players it is targeted towards other regulated and rapidly growing markets. Golden Galaxy’s software is provided and maintained by Playtech Limited, the world’s largest online gaming software supplier traded on the London Stock Exchange�� Main Market, offering cutting-edge, value added solutions to the industry’s leading operators. Since Playtech’s inception in 1999 the world�� leading online gaming software company, and bears the official approval of the Technical System Testing of North America Inc. (TST), which has periodically verified that the games are true and fair.

• [By Peter Graham]

  Small cap entertainment or gaming stocks Soul and Vibe Interactive Inc (OTCBB: SOUL), Elray Resources Inc (OTCMKTS: ELRA) and Players Network (OTCMKTS: PNTV) focus on entertaining consumers. However, its important to remember that consumers can be very fickle when it comes to entertainment or games. So should you be entertaining any of these small caps? Here is a closer look and a reality check:

Hot Low Price Companies To Invest In Right Now: Silicon Image Inc.(SIMG)

Silicon Image, Inc. provides wireless and wired high-definition (HD) connectivity solutions that enable the distribution and presentation of HD content for consumer electronics, mobile, and personal computer (PC) markets. It delivers its technology via semiconductor and intellectual property products. The company?s consumer electronics products include high-definition multimedia interface (HDMI) port processors, HDMI and mobile high-definition link (MHL) transmitters, MHL-to-HDMI bridges, and HDMI receiver products; PC products comprise MHL/HDMI-to-HDMI bridges and digital visual interface receivers; and storage products consist of a line of serial advanced technology attachment controllers used in PC, DVR, and network attached storage applications. Its products are deployed by the electronics manufacturers in various devices, such as desktop and notebook PCs, DTVs, Blu-ray disc players, and audio-video receivers, as well as mobile phones, tablets, and digital cameras. The company, through its subsidiaries, provides manufacturers comprehensive standards interoperability and compliance testing services; and acts as an agent for promoting and administering HDMI and MHL specifications, and for licensing the serial port memory technology memory interface specification. It sells its products to original product manufacturers worldwide through direct sales force, as well as through a network of distributors and manufacturer?s representatives. The company has operations in the United States, Taiwan, Japan, China, and Korea, as well as Europe and internationally. Silicon Image, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Technology shares dropped by 0.14 percent in the US market today. Among the sector stocks, Liquidity Services (NASDAQ: LQDT) was down more than 11.2 percent, while Silicon Image (NASDAQ: SIMG) tumbled around 6.7 percent.

• [By Roberto Pedone]

  The exact same setup is shaping up in shares of small-cap semiconductor firm Silicon Image (SIMG). Like HCP, this firm is stuck trading in a downtrending channel. Unlike HCP, trendline resistance is a whole lot stronger in this stock. Shares have gotten swatted down on each of the last eight attempts through that ceiling; with shares at resistance again, the high-probability move is to the downside.

  Again, relative strength has been terrible since the summer; SIMG is underperforming the S&P by a considerable margin. Downtrending relative strength is a cardinal sin for stocks, so with shares sitting at resistance, now's a stellar place to be a seller. While support has been pretty strong along the way down, SIMG's previous penetrations through S1 should be a big red flag that buyers are skittish.

  SIMG is in a textbook downtrend right now. Don't get caught on the wrong side of the trade.

• [By Bryan Murphy]

  Quick - what do Simon Property Group Inc. (NYSE:SPG), Dr. Pepper Snapple Group Inc. (NYSE:DPS), and Silicon Image, Inc. (NASDAQ:SIMG) have in common? If you said absolutely nothing, you'd be about 99% right. There's one common thing between SIMG, SPG, and DPS right now, however. What's that? All three stocks are on my personal "buy" list this week.

Hot Low Price Companies To Invest In Right Now: Avis Budget Group Inc.(CAR)

Avis Budget Group, Inc., together with its subsidiaries, provides car and truck rentals, and ancillary services to businesses and consumers worldwide. It supplies rental cars to the premium commercial and leisure segments of the travel industry under the Avis brand; and to the value-conscious segments of the industry under the Budget brand. The company operates or licenses the Avis car rental system that includes approximately 5,200 locations; and operates approximately 2,100 Avis car rental locations in on-airport and local rental markets; and operates or licenses the Budget vehicle rental system comprising approximately 3,050 car rental locations, and operates approximately 1,100 Budget car rental locations. It also operates local and one-way truck rental businesses, and operates a combined fleet of approximately 26,000 trucks, which are rented through a network of approximately 1,850 dealers and 300 company-operated locations in the continental United States serving the consumer and light commercial sectors. In addition, the company engages in the sale and rental of optional products and services, including loss damage waivers; insurance products, such as additional/supplemental liability insurance or personal accident/effects insurance; automobile towing equipment and other moving accessories consisting of hand trucks, furniture pads, and moving supplies; and products for driving convenience, such as where2 GPS navigation units, optional roadside assistance, fuel service options, and electronic toll collection, as well as other ancillary products and services comprising rental of satellite radio units and child safety seats. Its rental fleet comprises approximately 393,000 vehicles. The company was formerly known as Cendant Corporation. Avis Budget Group, Inc. was founded in 1946 and is headquartered in Parsippany, New Jersey.

Advisors' Opinion:

• [By Rich Duprey]

  Building on its acquisition of Zipcar earlier this year,�Avis Budget Group (NASDAQ: CAR  ) just announced it is buying deep-value rival�Payless Car Rental, the sixth-largest�car rental company�in North America, in a $50 million deal. The deal marks the continued consolidation of the car rental industry, one that is already heavily rolled up into just a few hands.

• [By Vera Yuan]

  ��uto rental company Avis Budget Group, Inc. (CAR) reported strong quarterly results, and pricing appeared to be in line with management�� plans in the important summer months. We estimate the company could generate $4 per share in free cash flow per share in 2015. In addition, competitor Hertz announced a multi-period earnings restatement, potentially reducing the probability that one of Avis�� two main competitors will take more aggressive pricing actions.

• [By Kevin Chen]

  After acquiring Zipcar for $500 million in January, Avis� (NASDAQ: CAR  ) has expanded Zipcar into 11 airports across North America in the past several weeks. It announced eight of the openings this week following three last month.

Hot Low Price Companies To Invest In Right Now: Dycom Industries Inc.(DY)

Dycom Industries, Inc. provides specialty contracting services in the United States and Canada. The company?s services include engineering services, which comprise the design of service area concept boxes, terminals, buried and aerial drops, transmission and central office equipment, administration of feeder and distribution cable pairs, and fiber cable routing and design for telephone companies; and make-ready studies, strand mapping, field walk-out, computer-aided radio frequency design and drafting, and fiber cable routing and design for cable television multiple system operators. The company also provides construction, maintenance, and installation of splice fiber, copper, and coaxial cables to telephone companies; installation and maintenance of customer premise equipment, including set top boxes and cable modems to cable television multiple system operators; and premise wiring services, which include installation, repair, and maintenance of telecommunications infrast ructure within improved structures to various corporations, and state and local governments. In addition, Dycom offers underground utility locating services, such as locating telephone, cable television, power, water, sewer, and gas lines to various utility companies. Further, it provides construction and maintenance services for electric utilities and others, which include installing and maintaining overhead and underground power distribution lines, as well as maintenance and installation of underground natural gas transmission and distribution systems. The company was founded in 1969 and is based in Palm Beach Gardens, Florida.

Advisors' Opinion:

• [By Brian Pacampara]

  What: Shares of telecom contractor Dycom Industries (NYSE: DY  ) climbed 11% today after its quarterly results and outlook topped Wall Street expectations.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Dycom Industries (NYSE: DY  ) , whose recent revenue and earnings are plotted below.

Hot Low Price Companies To Invest In Right Now: Alps Jefferies TR/J CRB Global Commodty Eq Idx (CRBQ)

Jefferies | TR/J CRB Global Commodity Equity Index Fund (the Fund), formerly Thomson Reuters/Jefferies CRB Global Commodity Equity Index Fund, is an exchange traded fund (ETF). The Fund seeks investment results that replicate as closely as possible the price and yield performance of the Thomson Reuters/Jefferies In-The-Ground CRB Global Commodity Equity Index (the Index). The Index is a modified capitalization-weighted, float-adjusted, rules-based index designed to track the overall performance of a global universe of listed companies engaged in the production and distribution of commodities and commodity-related products and services in the sectors, such as agriculture, base/industrial metals, energy and precious metals. ALPS Advisors, Inc. is the investment adviser for the Fund. Arrow Investment Advisors, LLC is the investment sub-adviser for the Fund. Advisors' Opinion:

• [By Richard Stavros]

  Whereas in the 1970s there were limited ways to hedge against inflation, now there is a cornucopia of currency and international commodities instruments that can not only hedge against inflation but other global shocks, such as market bubbles and even war.
  
  And it is these very scenarios that investors have been worried about. Since the beginning of the year, stocks, bonds and just about any investment you can think of have gyrated wildly at various times amid concerns of war, inflation and the possibility that the U.S. equity market is overvalued and headed for a correction.
  
  In response, some market analysts in Bloomberg news reports have offered any number of wildly unsubstantiated statements for why investors should ignore today’s perils. They dismiss the danger posed by Russia�� annexation of Ukraine�� Crimea region (��utin will stop short of other countries or war with the West��. They also argue that the Federal Reserve chairwoman misspoke (��anet Yellen really didn�� mean a rate hike is coming soon. Inflation is under control. It was a rookie mistake��.
  
  For my money, here’s the most outrageous: The Shiller Cyclically adjusted P/E metric which has predicted the 1929, 2000 and 2007 downturns doesn�� apply (��uggests only a slightly expensive market with low to moderate returns going forward on average��.
  
  With new records being set by the S&P 500 in the last few months, it stands to reason that some investors have not needed much convincing to stay all in and buying. This mindset has prevailed, even as the impact of a Russian war or conflict, runaway inflation or a market correction could be devastating to investor portfolios, taking years to recover.
  
  If you��e never thought of certain investments as “insurance,” it�� time to start now. Protecting wealth is as important as building wealth. And as previously mentioned, we have found that the Inflation Survival Letter�� Thri

Hot Low Price Companies To Invest In Right Now: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:

• [By Dan Caplinger]

  Yet J&J isn't satisfied with what it already has. Last week, the company joined with Pharmacyclics (NASDAQ: PCYC  ) to seek approval for their lymphoma drug ibrutinib. J&J will get a 50% share of any profit from the venture, and J&J cited a Piper Jaffray estimate that just one of its indications could produce sales of more than $4 billion.

• [By Keith Speights]

  Last year, Pharmacyclics (NASDAQ: PCYC  ) shares gained a whopping 280%. That was enough to land the biotech a spot on The Motley Fool's list of top health-care stocks in 2012. How is 2013 looking so far? Shares have gained more than 30% year to date but have been anemic since early March.

• [By Sean Williams]

  Very few breakthrough therapies have been approved up to this point -- then again, we're only working with about 100 days for the Food and Drug Administration to have assigned such a designation. Vertex Pharmaceuticals'�received the first two "breakthrough therapy" designations from the FDA for two cystic fibrosis treatments, of which both involve the use of the already FDA-approved Kalydeco. The more intriguing "breakthrough therapy" designation is Pharmacyclics' (NASDAQ: PCYC  ) Ibrutinib for the treatment of two rare blood cancers, which analysts feel could have a peak sales value of $5 billion if approved.